Burning Rock Biotech (BNR) Net Income towards Common Stockholders (2019 - 2026)

Burning Rock Biotech's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 35.98% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$8.4 million (up 74.39% YoY), while the FY2025 annual figure was -$7.9 million, up 83.33% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.5 million, down from -$2.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$1.4 million in Q2 2025, with the low at -$41.2 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is -$16.8 million (2024), against an average of -$17.3 million.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders sank 57.61% in 2022, then soared 90.89% in 2025.
• Burning Rock Biotech's Net Income towards Common Stockholders stood at -$31.4 million in 2022, then gained by 27.12% to -$22.8 million in 2023, then soared by 51.26% to -$11.1 million in 2024, then surged by 80.26% to -$2.2 million in 2025, then slipped by 15.14% to -$2.5 million in 2026.
• Business Quant data shows BNR's Net Income towards Common Stockholders at -$2.5 million in Q1 2026, -$2.2 million in Q4 2025, and -$2.4 million in Q3 2025.